Research programme: recombinant human kallikrein 1 - Sinobiomed

Drug Profile

Research programme: recombinant human kallikrein 1 - Sinobiomed

Alternative Names: rhK1

Latest Information Update: 26 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Wanxing Bio-Pharmaceutical; Sinobiomed
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Kallikrein 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Peripheral vascular disorders; Stroke; Thrombosis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top